Ebvallo CUP-202227

Active substance

tabelecleucel

Holder

Pierre Fabre Medicament

Status

Running

Indication

Monotherapy for the treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Public documents

Approbation

Information for the patient

Informed consent

Last update

28/03/2023

Last updated on 13/02/2024